eLive.care SIGNED

Project "eLive.care" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

Treatment of chronic diseases create 80% of healthcare costs in the EU, annually €115 billion. The amount is continuously rising as the population ages and chronic diseases affect 8 out of 10 people aged 65 and older. However, 50-80% of chronic diseases can be prevented by reducing the risk factors and ensuring good living environment. The breakthrough innovative eLive.care -solution combines genomic tests and several at home measurements of health (ambulatory blood pressure monitor, blood glucose, cholesterol levels, sleep cycles, blood oxygen saturation) and environment (interior air quality monitors). With the support of Artificial Intelligence, the solution guides the user to independently, medically effectively and based on individual risk-factors prevent chronic diseases and their disadvantages. With the support of eLive.care -innovation several significant chronic diseases (such as cardiovascular diseases, type 2 diabetes and sleep apnea) can be detected prior to experiencing any symptom and therefore prevented. The impacts of at home preventive care are huge. By 2025 1.1M eLive.care -devices sold, 8.8M manual and 3.9 billion (meaningful) automatic measurements done, 60k chronicity of the disease prevented, €600M saving in healthcare costs (up to 80% savings in long-term healthcare costs), €560M revenue, and 550 direct and 2300 indirect workplaces. The solution target to the market opportunity of 3.2 billion 30-year-old middle-class consumers and TAM of €5 billion. The demand is proven with €75k pre-sales and sales funnel of €76k. The solution is currently under piloting and will be launched to the market with in-house and partner sales during 2019. eLive Ecosystem Oy has enthusiastic team of nine with core competence in medical, technical and business development as well as strong partner network to support the commercialisation and scale-up.